244 related articles for article (PubMed ID: 25616366)
1. Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.
Lewis SN; Garcia Z; Hontecillas R; Bassaganya-Riera J; Bevan DR
J Comput Aided Mol Des; 2015 May; 29(5):421-39. PubMed ID: 25616366
[TBL] [Abstract][Full Text] [Related]
2. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
[TBL] [Abstract][Full Text] [Related]
4. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
5. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
Daga PR; Polgar WE; Zaveri NT
J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
[TBL] [Abstract][Full Text] [Related]
6. Multi-conformational frame from molecular dynamics as a structure-based pharmacophore model for mapping, screening and identifying ligands against PPAR-γ: a new protocol to develop promising candidates.
Prabitha P; Shanmugarajan D; Kumar TDA; Kumar BRP
J Biomol Struct Dyn; 2022 Apr; 40(6):2663-2673. PubMed ID: 33140698
[TBL] [Abstract][Full Text] [Related]
7. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists using molecular modeling method.
Gee VM; Wong FS; Ramachandran L; Sethi G; Kumar AP; Yap CW
J Comput Aided Mol Des; 2014 Nov; 28(11):1143-51. PubMed ID: 25168706
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D
Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282
[TBL] [Abstract][Full Text] [Related]
11. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
12. Computational investigation of phytochemicals from
Omoboyowa DA; Singh G; Fatoki JO; Oyeneyin OE
J Biomol Struct Dyn; 2023; 41(12):5568-5582. PubMed ID: 35773777
[TBL] [Abstract][Full Text] [Related]
13. Structure-based identification of novel PPAR gamma ligands.
da Silva FM; dos Santos JC; Campos JL; Mafud AC; Polikarpov I; Figueira AC; Nascimento AS
Bioorg Med Chem Lett; 2013 Nov; 23(21):5795-802. PubMed ID: 24075729
[TBL] [Abstract][Full Text] [Related]
14. Discovery of high affinity ligands for β2-adrenergic receptor through pharmacophore-based high-throughput virtual screening and docking.
Yakar R; Akten ED
J Mol Graph Model; 2014 Sep; 53():148-160. PubMed ID: 25137647
[TBL] [Abstract][Full Text] [Related]
15. Molecular Modeling Approach to Study the PPARγ-Ligand Interactions.
Al Sharif M; Tsakovska I; Alov P; Vitcheva V; Diukendjieva A; Pajeva I
Methods Mol Biol; 2019; 1966():261-289. PubMed ID: 31041755
[TBL] [Abstract][Full Text] [Related]
16. A computational study to identify the key residues of peroxisome proliferator-activated receptor gamma in the interactions with its antagonists.
Sharifi T; Ghayeb Y
J Biomol Struct Dyn; 2018 May; 36(7):1822-1833. PubMed ID: 28566016
[TBL] [Abstract][Full Text] [Related]
17. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors.
Ahmadi M; Nowroozi A; Shahlaei M
J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S
J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035
[TBL] [Abstract][Full Text] [Related]
19. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
Miyamae Y
Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046
[TBL] [Abstract][Full Text] [Related]
20. New strategy for receptor-based pharmacophore query construction: a case study for 5-HT₇ receptor ligands.
Kurczab R; Bojarski AJ
J Chem Inf Model; 2013 Dec; 53(12):3233-43. PubMed ID: 24245803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
